|
Dr. Holger Mueller, Investment
Director Dr. Holger Mueller is investment director with 3i Germany and head of the Munich healthcare team. He joined Technologieholding VC in 1997 as Investment Manager responsible for healthcare investments. Before he was Product manager with Biometra/Whatman. He holds a Ph.D. in Biochemistry and a diploma degree in molecular biology. |
 |
| Karen Hitschke,
Principal / Healthcare Team Karen Hitschke joined Apax Partners in October 1997 as a specialist in biotechnology. Karen received her MBA from INSEAD, where she graduated in 1997 with distinction. In addition, she holds a Masters Degree in Biology with a specialization in Cell Biology, Immunology and Biophysics. After finishing her studies in Constance (Germany) and Sussex (UK), she joined McKinsey & Company in Munich in 1994. During her time as a strategy consultant she focused on the food and chemical industry, where she performed studies on organizational restructuring and business process re-engineering. Karen is a board member of Cosmix, and was involved in several other transactions, including Metagen, BioImage and Wilex. |
 |
Rob Zegelaar, Senior Principal Robert Zegelaar joined Atlas Venture in 1987. With a Master of Science degree in Business Administration from the University of Groningen, Rob focuses on investments in healthcare. Board participation includes: |
 |
Prof. Dr. Jesper Zeuthen, Managing
Director Jesper Zeuthen has been working for the BankInvest Group as a consultant since 1988, and he decided to join us full time in spring 2000 working primarily with venture capital. Previously, Jesper Zeuthen has worked as Head of R & D at Novo Nordisk and Head of Research at The Danish Cancer Society. He is the author of more than 200 publications in immunology, cell biology and molecular biology and served as adjunct professor of biotechnology at the University of Copenhagen. |
 |
|
Prof. Dr. Horst Domdey,
CEO As well as holding the position of Managing Director & CEO at Bio-M AG, Prof. Dr. Horst Domdey is also Managing Director of the Innovation Centre for Biotechnology (IZB), Chairman of the Munich BioRegio Initiative and Co-founder of MediGene AG and Switch Biotech AG. He has vast experience in the field of Biochemistry having been a Postdoctoral fellow at numerous institutes including Max-Planck-Institut fur Biochemie, the Swiss Institute for Experimental Cancer Research (ISREC), University of California and the California Institute of Technology. Further to this, he was Associate Professor for Biochemistry at the Ludwig-Maximilians-Universitat Munchen for 4 years. |
 |
| Dr. Kai-Uwe Bindseil,
CEO Dr. Kai-Uwe Bindseil studied chemistry at Georg August University in Göttingen. In 1993, he wrote his doctoral thesis in bioorganic chemistry under the guidance of Prof. A. Zeeck. After a post-doctoral fellowship at Ciba-Geigy AG in Basle, he moved to AnalytiCon in 1994, where he is currently responsible for drug discovery, marketing and business development. As of mid-August he has become CEO of BioTOP. |
 |
| Dr. Marion Dörner,
Principal Marion joined Earlybird in 1999 as an associate in the healthcare group. From the beginning, she was involved in building Earlybird´s healthcare portfolio in Europe and the US. With a broad and international network she actively helps our portfolio companies to accomplish their value-creating milestones, and has accompanied several portfolio companies from Earlybird’s initial investment through subsequent financing rounds (i.e. amaxa, Bernina and GMD). She also actively assisted a European merger involving a portfolio company. Marion’s interests are centered around innovative technologies and products that serve to increase the R&D productivity of the pharmaceutical value chain. She joined Earlybird after her postdoctoral training in Molecular Biology at the Ludwig-Maximilians-University in Munich. She earned her PhD under the supervision of Prof. Dr. Svante Pääbo while working on genetic peculiarities of mammalian mitochondria. She has gained further research expertise in programs at Arizona State University in Phoenix, Arizona and at the Marine Biological Laboratory in Woods Hole, Massachusetts. Marion received a Dipl.- Biol. (MS equivalent) from the Ludwig-Maximilians-University in Munich. She is author of several articles which were published in peer reviewed journals and serves on the board of EUROPROTEOME AG. |
 |
Godelieve Quisthoudt-Rowohl, Member of the European Parliament, Quaestor Born on 18 June 1947, Etterbeek (Belgien) |
 |
| Peter Kuchenbuch,
Life Science Correspondent Peter Kuchenbuch (39) is life science correspondent with Financial Times Deutschland. He studied agriculture in Goettingen (Germany) and worked as a scientist in biotech projects. As a freelance journalist he published in magazines and TV for years. He was also responsible for studies and projects in the name of organizations like Friedrich-Ebert-Stiftung and Greenpeace. |
Dr. Jens A. Katzek, Managing
Director Dr. Jens Katzek, 39, biochemist by education and since March 2001 Managing Director of the German Association of Biotechnology Industries (DIB). During his professional career he was working in different positions on the regulation and public debate of genetic engineering. He was working as an Scientific advisor of the European Commission, the personal assistant of Edelgard Buhlman, Member of Parliament, now Minister for Research in Germany, and an environmental organisation. Before he joined DIB he was Head of Communication for the company KWS Seed AG. |
 |
Dr Ann Mills-Duggan,
Dr Ann Mills-Duggan is a Director in the GlaxoSmithKline Genetics & Discovery Ventures group. This innovative team seeks to maximise the value of non-core GSK assets outside the company. Ann has fifteen years pharmaceutical industry experience encompassing a variety of roles based in the UK and Switzerland. Following a number of years in research, she moved to join the GlaxoWellcome, later GlaxoSmithKline, Business Development group. Here Ann was responsible for Scientific Licensing, evaluating the science of potential licensing deals, and subsequently Alliance Management, ensuring effective post-deal management of collaborations. She joined the Genetics and Discovery Ventures group earlier this year and is responsible for assets deriving from European-based R&D operations. Dr Mills-Duggan holds a Ph.D. in Biochemistry and a Diploma Degree in Science Communication. |
 |
Hanns-Peter Wiese, Partner Hanns-Peter Wiese, Dipl.-Kfm., is a founding partner of Global Life Science Ventures and has eleven years experience in venture capital. His exposure to early stage investing in the life sciences reaches back to 1996, when he co-set up the predecessor fund Global Life Science L.P. as Managing Director of Life Science Ventures GmbH. Mr. Wiese also looks after the partnerships’ financial, legal and administrative issues which includes the monitoring of 13 portfolio companies following several exits through IPO/ M&A. Previously, he was a Director of Corporate Finance with Bayerische Vereinsbank, Director of their associated VC-fund Euro Synergies in Paris, and Investment Manager with 3i in Frankfurt. He speaks fluent English and French. |
 |
Dr. Andreas Wicki, Board
Member & CEO Dr. Wicki (42) is a successful healthcare entrepreneur and investor and currently leads the management team of HBM BioVentures AG, one of the leading investment companies with a life sciences focus. He was co-owner and CEO of ANAWA Laboratorien AG, a healthcare analytical services company which was successfully sold in 1998 to MDS Inc. (NYSE MDZ; TSE MDS), a major healthcare services and clinical research organization with more than ten thousand employees. He was Senior Vice President European Analytical Services of MDS. He was also the founder and CEO of Clinserve AG, a rapidly growing clinical trial services company. Dr. Wicki has over 10 years of experience in the pharma and biotechnology industry and has been advising APAX and Bank Vontobel on their private equity investments in that sector since 1992. Dr. Wicki holds a Master of Science and a Ph.D. in chemistry and molecular biology from the University of Berne, Switzerland. Dr. Wicki is on the Board of Directors of the healthcare companies Basilea Pharmaceutica AG, Buchler GmbH, Cosmix GmbH and MDS Pharma Services Switzerland AG. |
 |
Susan Searle, Managing
Director Susan Searle is an Oxford educated Chemist. She started her career working for Shell Chemicals and moved to Shell International working as a business and product development manager covering plastics, resins and base chemicals. After 3 years she moved to the Bank Of Nova Scotia where she was appointed marketing manager for gold bullion products where she developed a European client base and secured backing for a new business; gold leasing. Susan then entered the technology transfer business and spent a year in Australia developing and licensing technologies from the science and engineering faculty at Monash University. She established a network of investors and launched a technology precinct which brought some 700 local companies together. On her return for the UK she spent several months consulting for Imperial who were not at that stage ready to invest seriously in technology transfer. She joined the Signet group, a retail organisation and held a variety of roles which involved troubleshooting and re-organising parts of the business and acting as an internal consultant. She established an import operation in Italy re-sourcing product direct to supplier and traded gold for the company. She ran a buying team managing stock control, range selection and merchandising. However, bored of retail products, Susan saw the opportunity to join IMPEL, Imperial’s technology transfer company, in 1994. The team at the time was small, she joined as a senior executive managing science and engineering technologies. IMPEL has now evolved into Imperial College Innovations Ltd and grown to a staff of 23. It has some 53 spin out companies which have been established based on Imperial’s research and some 40 more in the pipeline. IC Innovations has a “hands on” approach to establishing new companies. Susan has been instigative in the development and growth of the organisation including involvement in a number of successful government bids for seed funds and exploitation/incubation platforms. Susan became Commercial Director of IC Innovations in 1999 and was appointed Managing Director in January 2002. She currently holds directorships on a number of boards; Casect (gas detection systems), Powerlase (laser systems), Adapative Screening (drug discovery), Nanobiodesign (diagnostics), Holoscan (ultrafast imaging). She was on the board of Turbogenset, Imperial’s leading success which floated in 2000 and realised £10.2m in return for 25% of Imperial’s holding. |
 |
Prof. Chris Toumazou, Head
of Department, Bioengineering Chris Toumazou, PhD, FIEEE is a Professor of Circuit Design in the Department of Electrical and Electronic Engineering, and Head of the Department of Bioengineering at Imperial College, London, U.K. He received his PhD from Oxford-Brookes University in collaboration with UMIST Manchester in 1986. His research interests include high frequency analogue integrated circuit design in bipolar, CMOS and SiGe technology for RF electronics and low-power electronics for biomedical applications. He has authored or co-authored some 300 publications in the field of analogue electronics and is a member of many professional committees. Chris has 7 patents in the field of RF and low power electronics. Chris was given the title of the youngest Professor ever to be appointed at Imperial College at the age of 33. He is a past Chairman for the Analog Signal Processing Committee of the IEEE Circuits and Systems (CAS) Society and past Vice-President of Technical Activities for the IEEE CAS Society. He is currently on the IEEE Society's Board of Governors. He is the Editor-in-Chief of the IEEE Transactions on Circuits and Systems - II: Analog and Digital Signal Processing, and an Honorary Editor of the UK IEE Electronics Letters. He is co-winner of the IEE 1991 Rayleigh Best Book Award for Analog IC Design: the Current-Mode Approach. He is also a recipient of the 1992 IEEE CAS Outstanding Young Author Award for his work on High Speed GaAs Op-amp Design. The IEEE is the main USA Electrical and Electronic Engineering Society. In January 2000 Chris was elected to the fellowship of the IEEE for contributions to current-mode analogue design. Chris is currently head of the Bioengineering Department where he has been pivotal in fundraising and developing the bionics/medical devices area of Imperial College. He has been involved with a number of commercial ventures, including the development of the world's first analogue and digital mobile phone for Thailand which was fully type approved in 2000 and a totally implantable analogue cochlear prosthesis, which will undergo clinical trials in September 2001. Chris is chairman and Director of a spin off company out of Imperial (Toumaz Technology Ltd), which develops IP cores and hardware products for RF and ultra low power analogue silicon for biomedical applications. |
 |
Conny Bogentoft, Managing
Director Conny Bogentoft is Managing Director of Karolinska Innovations AB and Associate Professor at the University of Uppsala. He has published 160 papers and abstracts in Organic Chemistry, Medicinal Chemistry, Biopharmaceuticals and Drug Delivery. Conny Bogentoft has spent 27 years in the Swedish Pharmaceutical Industry in many positions as Director or VP of Research and CEO. He has been chairman of the Swedish Pharmaceutical Society and is an Advisor to the Medical Product Agency. He holds board positions in several small Start Up companies as well as in the Institute for Surface Chemistry. |
 |
Stan Yakatan, Chairman After 30 years as a successful CEO, entrepreneur,and operational manager, Stan Yakatan has dedicated the last 7 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive and in several instances serving as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch, provided him with management and corporate finance acumen that he enjoys sharing with others. He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world’s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, “Capital Raising for the Technology-Based Start-Up” and “The Need to be Global in the Quest for Capital and Partners”. Rick Biondi, Editor of Lab Business Magazine stated, “Mr Yakatan is a venture capital raising Guru and it is part of his genetic make up.” He currently serves as the strategic advisor to the state government of Victoria, Australia and is the Chairman of Katan Associates International with headquarters in New York City. |
 |
Mark Clement, MD of European
Operations Mark Clement joined Merlin Biosciences in March 2000. A Chartered Accountant and Fellow of the Securities Institute he has over 17 years corporate finance experience with Coopers and Lybrand, Price Waterhouse, Hoare Govett, and more recently Panmure Gordon. In 1992 he was co-founder and Finance Director of Celsis International plc. He formed his own corporate finance consultancy in October 1997. He has extensive experience in negotiating and managing collaborations and consolidations both in the US and in Europe. He is a non-executive director of investee companies of the Merlin Biosciences Fund and of the Merlin General Partner II Ltd. |
 |
Mr Adi Seffer, Partner
Adi Seffer is head of the Morgan Lewis’ Technology Practice in Frankfurt. His practice focuses on tech-driven transactions for Technology(TMT)- and Biotechnology clients and the financial community. He handles e-commerce and copyright-matters, IP/IT and Biotech related agreements, M&A transactions and private and public financings. Mr. Seffer’s transnational dispute experience includes injunctive relieves, ICC arbitration, involving U.S. clients and other foreign clients, acting as a panel arbitrator and several adhoc arbitrations under various German arbitration rules. Adi Seffer is president of the world-wide operating International Association of Young Lawyers (AIJA). He is a member of the German Association for Intellectual Property and Copyright Law (GRUR), Licensing Executives Society, and the German Association of Computer Law. Mr. Seffer is nominated by Legal Media Group, London as one of only 30 lawyers worldwide as a leading lawyer in both Telecoms and IT. Mr. Seffer studied law at the Universities of
Regensburg, Frankfurt am Main and Munich. He received his bachelor’s
degree in 1985 and his law degree in 1990. His legal education was
supplemented by training in International Law in London (1983) and
Comparison of Laws in Strasbourg, France (1984 and 1985). |
 |
Dr Christian Zschocke,
Managing Director Christian Zschocke is the Managing Partner of the Morgan Lewis’ Frankfurt office. His practice concentrates on mergers and acquisitions, in particular takeover law, as well as on EU and German antitrust law. He has been the external advisor to the German Takeover Commission for several years. Dr. Zschocke is a regular speaker at seminars, and an author of numerous publications on corporate and antitrust law, including a bilingual commentary on the German Takeover Code, a bilingual commentary on the German Stock Corporation Act, as well as monthly reports on current takeover offers and the development of European and German takeover law in the magazine “FINANCE”. Dr. Zschocke, a German national, has been a member of the Cologne Bar since 1990. In addition to earning a doctorate in law from Hamburg University, he is qualified as a Licenciado en derecho under Spanish law. |
 |
Dr. Michael Steinmetz, General
Partner Dr. Steinmetz is General Partner at Medical Portfolio
Management (MPM) Capital, headquartered in Cambridge, MA, USA, an
investment firm focusing on investments in private and more recently
also public biotechnology and medical device companies in the U.S.
and Europe. In 1997, he became a partner at MPM and the Bellevue
Group in Zürich, Switzerland, and helped to establish the BioVentures
family of funds representing two of the largest, life science venture
capital funds. Since then the first fund, the $230 million BioVentures
I fund has been fully committed encompassing a total of 25 healthcare
companies. Early in 2000, a second fund, the $600 million BioVentures
II fund, was established, which is currently being invested actively
by a team of 15 professionals, including 5 General Partners, operating
out of three offices in Cambridge (USA), San Francisco (USA) and
Munich (Germany). A complete list of portfolio companies of the
two funds can be found on MPM’s website at www.mpmcapital.com.
Dr. Steinmetz is currently on the Board of Directors at Acorda Therapeutics,
Arena Pharmaceuticals, Atugen, Caliper Technologies, Epigenomics,
IDEA, Macrogenics and Xcyte Therapies and is Chairman of the Board
at Coelacanth Corporation and GPC Biotech. Two of these companies,
Atugen and GPC Biotech, he helped get started as Acting CEO for
a year each. |
 |
André Lamotte, Founder Held various management positions at Sandoz Ltd. and at Pasteur-Merieux Vaccines Inc. before he created, together with Harvard University, the venture capital fund MSP, of which he is still a Managing General Partner. MSP has a proven track record in creating and growing companies. André Lamotte is deeply involved in the U.S. venture capital community and has built a broad healthcare network in North America and Europe. He holds an MBA from Harvard Business School and a Sc.D. from MIT. He is founder and Managing Director of NMT New Medical Technologies, a Swiss Venture Capital Company that is focussing exclusively on the healthcare sector. |
 |
Dr. Romeo Paioni, Head of
Scientific and External Affairs Romeo Paioni was appointed Head of Scientific and External Affairs of Novartis Pharma Development in January 1999. Prior to that, he was Head of Novartis Preclinical Development and Project Management, Basel Operations. Before assuming this responsibility at the time of the merger of CIBA and Sandoz in 1997, R. Paioni filled various positions within the Pharmaceutical Division of CIBA. From 1990 to 1997 he was Head of CIBA’s Pharma Research at Headquarters in Basel. Since 2001 R. Paioni is Vice-President of the BioValley Platform Basel Society, of which he was a founder-member in 1998. Romeo Paioni studied chemistry at the Universities of Basel (Diploma) and Bern (PhD) and was a Post-Doctoral Fellow with Nobel Laureate Prof. R. B. Woodward at the Woodward Research Institute in Basel and at Harvard University, Cambridge, Mass. |
 |
Michael Lytton, General
Partner Michael Lytton is a General Partner of Oxford Bioscience Partners. Prior to that, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Acambis plc, ActivX Biosciences Inc., Descartes Therapeutics, Inc, GPC Biotech AG, Graffinity Pharmaceuticals AG, Psychiatric Genomics Inc, and Rib-X Pharmaceuticals, Inc. Mr. Lytton is a member of the Research and Technology Development Committee of the Beth Israel Deaconess Medical Center (an affiliated Harvard teaching hospital). Mr. Lytton is a member of the Board of Overseers and the Research and Technology Committee of the Center for Blood Research, Harvard Medical School. Mr. Lytton is also a member of the Translational Research Subcommittee of the Brigham and Women’s Hospital (a Harvard hospital). Mr. Lytton also serves as a member of the Biotech Advisory Committee to Connecticut Innovations, a quasi-public seed venture fund for Connecticut-based start-up biomedical companies. Mr. Lytton writes a column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. Mr. Lytton was a summa cum laude graduate of Princeton University and a recipient of a Fulbright Scholarship for study at the University of London. Mr. Lytton received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine. |
 |
Dr. Silvano Fumero, Dr Silvano Fumero is Senior Executive Vice President, Head of Research & Pharmaceutical Development at the Serono Group in Geneva, since April 1996. Dr Fumero’s career started in the 1970s, when he filled a succession of research positions in the fields of biochemistry, steroid receptors, mutagenesis and toxicology. After two years in Brussels at the EEC as toxicologist (DG III Chemical Industry), Dr Fumero was appointed General Manager in 1987 of Istituto di Ricerche Biomediche A. Marxer (RBM) in Ivrea, the first Italian contract research organisation. He became Vice President of LCG Bioscience in London, a division of Serono which is a network of CRO's offering R&D services to pharmaceutical and biotechnology companies. He is also contract professor in “Organisation and Planning of R&D”, at the University of Turin (Faculty of Science, Biotechnology). |
 |
|
Bernard Gilly, Partner Bernard GILLY is partner at Sofinnova Partners
and invests in life sciences. Bernard is a graduate of Ecole Nationale
d'Agronomie and has a PhD in biology and bio-economics from Université
de Rennes I and the University of Rhode-Island, as well as an MBA
from INSEAD. He began his career as a scientist at the Institut
National de la Recherche Agronomique (INRA). He then worked for
four years as a consultant for the Food and Agriculture Administration
(FAO) and the International Monetary Fund (IMF). In 1988, he joined
Institut Mérieux, the world’s human vaccine leader.
From 1990 to 1994 he was Vice-President R&D at Pasteur Mérieux
Connaught (PMsv). In 1992, Bernard was named President and CEO of
Transgene, a French biotechnology company, at the time a 63% subsidiary
of PMsv. Having redefined the strategy of Transgene towards gene
therapy, he successfully grew the company to its IPO in April 1998
on the Nasdaq and the Nouveau Marché. He also sits on the Boards of the Institut National de la Recherche Médicale (INSERM), the Centre National de la Recherche Scientifique (CNRS) and the Ecole Normale Supérieure de Lyon (ENS Lyon). |
 |
Robert Wyss, Head of SWX
New Market After graduating as BBA from University of Berne, head of the research team for the Swiss stock market at Zürcher Kantonalbank in Zürich (1987 – 1994). Berner Kantonalbank, Bern: responsible for consulting and portfolio management for institutional investors (1994 – 1997). From 1997 to 1998 responsible for investment strategy and portfolio management at the Private Bank Von Graffenried in Berne. Evaluation of venture projects for Berne Venture Ltd. Since June 1998 head of Key Account Issuers and responsible for the SWX New Market at the SWX Swiss Exchange. |
 |
Dr. Hubert Birner, Partner, Dr. Birner serves on the boards of Direvo Biotech AG (Cologne), Merix Bioscience Inc. (Durham, NC, and Erlangen), Jerini AG (Berlin) and Cell Based Delivery (Providence, RI) and represents the interests of TVM at Neuro3d (Mulhouse). He came to TVM in October 2000. Previously, he was Head of Business Development Europe and Director of Marketing Germany at AstraZeneca. Dr. Birner joined AstraZeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a consultant, he gained extensive experience in R&D management, marketing & sales as well as joint venture structuring and business development. Dr. Birner was also an Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. He holds an MBA from Harvard Business School and a "summa cum laude" doctoral degree in biochemistry from Ludwig-Maximilians-University Munich. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding fundamental research in metabolic diseases. |
 |
Nick Lowcock, Managing Director
- European Healthcare Team Mr Lowcock has been with Warburg Pincus since 1994. Prior to joining Warburg Pincus, he was with the Boston Consulting Group and previously worked in the pharmaceutical industry in the United Kingdom. He is a director of The Medicines Company Inc., Eurand B.V., Leciva Pharmaceutical Holdings B.V., Strakan Group Ltd., Proskelia B.V. and Pharmaidea B.V. Mr Lowcock is also on the board of Project Hope UK, a charity devoted to improving healthcare in developing nations. Mr Lowcock has an MBA from Wharton. |
 |